Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
The Journal of clinical investigation.
Times cited: 215
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.
Times cited: 223